vs

Side-by-side financial comparison of First Foundation Inc. (FFWM) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $48.4M, roughly 1.6× First Foundation Inc.). On growth, First Foundation Inc. posted the faster year-over-year revenue change (421.7% vs -36.9%). MEDIFAST INC produced more free cash flow last quarter ($-6.6M vs $-35.2M). Over the past eight quarters, First Foundation Inc.'s revenue compounded faster (-2.7% CAGR vs -34.4%).

John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

FFWM vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.6× larger
MED
$75.1M
$48.4M
FFWM
Growing faster (revenue YoY)
FFWM
FFWM
+458.6% gap
FFWM
421.7%
-36.9%
MED
More free cash flow
MED
MED
$28.6M more FCF
MED
$-6.6M
$-35.2M
FFWM
Faster 2-yr revenue CAGR
FFWM
FFWM
Annualised
FFWM
-2.7%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FFWM
FFWM
MED
MED
Revenue
$48.4M
$75.1M
Net Profit
$-8.0M
Gross Margin
69.4%
Operating Margin
-97.5%
-10.4%
Net Margin
-97.9%
Revenue YoY
421.7%
-36.9%
Net Profit YoY
43.0%
EPS (diluted)
$-0.09
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FFWM
FFWM
MED
MED
Q4 25
$48.4M
$75.1M
Q3 25
$63.6M
$89.4M
Q2 25
$51.4M
$105.6M
Q1 25
$71.4M
$115.7M
Q4 24
$9.3M
$119.0M
Q3 24
$9.2M
$140.2M
Q2 24
$57.5M
$168.6M
Q1 24
$51.1M
$174.7M
Net Profit
FFWM
FFWM
MED
MED
Q4 25
$-8.0M
Q3 25
$-146.3M
$-2.3M
Q2 25
$-7.7M
$2.5M
Q1 25
$6.9M
$-772.0K
Q4 24
$-14.1M
Q3 24
$-82.2M
$1.1M
Q2 24
$3.1M
$-8.2M
Q1 24
$793.0K
$8.3M
Gross Margin
FFWM
FFWM
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
FFWM
FFWM
MED
MED
Q4 25
-97.5%
-10.4%
Q3 25
-92.7%
-4.6%
Q2 25
-21.1%
-1.0%
Q1 25
8.8%
-1.1%
Q4 24
-247.7%
0.6%
Q3 24
-1276.7%
1.5%
Q2 24
4.6%
-4.7%
Q1 24
-0.2%
4.5%
Net Margin
FFWM
FFWM
MED
MED
Q4 25
-97.9%
Q3 25
-230.1%
-2.5%
Q2 25
-15.0%
2.3%
Q1 25
9.7%
-0.7%
Q4 24
-152.2%
Q3 24
-896.9%
0.8%
Q2 24
5.4%
-4.8%
Q1 24
1.6%
4.8%
EPS (diluted)
FFWM
FFWM
MED
MED
Q4 25
$-0.09
$-1.64
Q3 25
$-1.78
$-0.21
Q2 25
$-0.09
$0.22
Q1 25
$0.08
$-0.07
Q4 24
$-0.24
$0.08
Q3 24
$-1.23
$0.10
Q2 24
$0.05
$-0.75
Q1 24
$0.01
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FFWM
FFWM
MED
MED
Cash + ST InvestmentsLiquidity on hand
$1.6B
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$912.6M
$198.9M
Total Assets
$11.9B
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FFWM
FFWM
MED
MED
Q4 25
$1.6B
$167.3M
Q3 25
$1.7B
$173.5M
Q2 25
$1.1B
$162.7M
Q1 25
$1.0B
$164.6M
Q4 24
$1.0B
$162.3M
Q3 24
$1.1B
$170.0M
Q2 24
$1.4B
$163.5M
Q1 24
$1.6B
$156.4M
Stockholders' Equity
FFWM
FFWM
MED
MED
Q4 25
$912.6M
$198.9M
Q3 25
$917.9M
$214.7M
Q2 25
$1.1B
$216.0M
Q1 25
$1.1B
$211.0M
Q4 24
$1.1B
$210.1M
Q3 24
$1.1B
$207.3M
Q2 24
$933.2M
$205.3M
Q1 24
$928.7M
$211.0M
Total Assets
FFWM
FFWM
MED
MED
Q4 25
$11.9B
$248.0M
Q3 25
$11.9B
$268.2M
Q2 25
$11.6B
$269.3M
Q1 25
$12.6B
$280.0M
Q4 24
$12.6B
$284.2M
Q3 24
$13.4B
$291.2M
Q2 24
$13.7B
$293.5M
Q1 24
$13.6B
$302.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FFWM
FFWM
MED
MED
Operating Cash FlowLast quarter
$-31.9M
$-5.3M
Free Cash FlowOCF − Capex
$-35.2M
$-6.6M
FCF MarginFCF / Revenue
-72.8%
-8.8%
Capex IntensityCapex / Revenue
6.9%
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-45.9M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FFWM
FFWM
MED
MED
Q4 25
$-31.9M
$-5.3M
Q3 25
$9.2M
$12.1M
Q2 25
$-16.3M
$-3.4M
Q1 25
$-552.0K
$3.4M
Q4 24
$-8.7M
$-4.9M
Q3 24
$14.2M
$9.1M
Q2 24
$-9.1M
$13.1M
Q1 24
$7.2M
$7.3M
Free Cash Flow
FFWM
FFWM
MED
MED
Q4 25
$-35.2M
$-6.6M
Q3 25
$8.6M
$10.8M
Q2 25
$-16.7M
$-4.8M
Q1 25
$-2.5M
$1.9M
Q4 24
$-11.4M
$-7.2M
Q3 24
$13.4M
$7.7M
Q2 24
$-9.4M
$11.1M
Q1 24
$5.9M
$5.4M
FCF Margin
FFWM
FFWM
MED
MED
Q4 25
-72.8%
-8.8%
Q3 25
13.5%
12.0%
Q2 25
-32.4%
-4.5%
Q1 25
-3.5%
1.6%
Q4 24
-123.5%
-6.1%
Q3 24
146.2%
5.5%
Q2 24
-16.3%
6.6%
Q1 24
11.6%
3.1%
Capex Intensity
FFWM
FFWM
MED
MED
Q4 25
6.9%
1.8%
Q3 25
1.0%
1.5%
Q2 25
0.8%
1.3%
Q1 25
2.8%
1.3%
Q4 24
29.4%
1.9%
Q3 24
9.0%
1.0%
Q2 24
0.4%
1.1%
Q1 24
2.5%
1.1%
Cash Conversion
FFWM
FFWM
MED
MED
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
-0.08×
Q4 24
Q3 24
8.04×
Q2 24
-2.96×
Q1 24
9.09×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons